Journal
ONCOTARGET
Volume 8, Issue 27, Pages 44366-44378Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.17875
Keywords
stem cell transplantation; interleukin-15; cytokine therapy; graft-versus-tumor activity; animal models
Categories
Funding
- Altor BioScience Corporation
Ask authors/readers for more resources
Interleukin-15 (IL-15) is a potent cytokine that increases CD8(+) T and NK cell numbers and function in experimental models. However, obstacles remain in using IL-15 therapeutically, specifically its low potency and short in vivo half-life. To help overcome this, a new IL-15 superagonist complex comprised of an IL-15N72D mutation and IL-15RaSu/Fc fusion (IL-15SA, also known as ALT-803) was developed. IL-15SA exhibits a significantly longer serum half-life and increased in vivo activity against various tumors. Herein, we evaluated the effects of IL-15SA in recipients of allogeneic hematopoietic stem cell transplantation. Weekly administration of IL-15SA to transplant recipients significantly increased the number of CD8(+) T cells (specifically CD44(+) memory/activated phenotype) and NK cells. Intracellular IFN-(Y). and TNF-alpha secretion by CD8(+) T cells increased in the IL-15SA-treated group. IL-15SA also upregulated NKG2D expression on CD8(+) T cells. Moreover, IL-15SA enhanced proliferation and cytokine secretion of adoptively transferred CFSE-labeled T cells in syngeneic and allogeneic models by specifically stimulating the slowly proliferative and nonproliferative cells into actively proliferating cells. We then evaluated IL-15SA's effects on anti-tumor activity against murine mastocytoma (P815) and murine B cell lymphoma (A20). IL-15SA enhanced graft-versus-tumor (GVT) activity in these tumors following T cell infusion. Interestingly, IL-15 SA administration provided GVT activity against A20 lymphoma cells in the murine donor leukocyte infusion (DLI) model without increasing graft versus host disease. In conclusion, IL-15SA could be a highly potent T-cell lymphoid growth factor and novel immunotherapeutic agent to complement stem cell transplantation and adoptive immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available